On November 6, Pfizer announced that the new indications for the world's first non-factorial innovative drug, Youruinine®, which only requires a fixed dose subcutaneous injection once a week, have been officially approved by the China National Drug Administration for routine preventive treatment of children and adults aged 12 and above with type A hemophilia with coagulation factor VIII inhibitors or type B hemophilia with coagulation factor IX inhibitors and adults weighing at least 35 kg to prevent bleeding or reduce the frequency of bleeding episodes.

On November 6, Pfizer announced that the new indications for the world's first non-factorial innovative drug, Youruinine®, which only requires a fixed dose subcutaneous injection once a week, have been officially approved by the China National Drug Administration for routine preventive treatment of children and adults aged 12 and above with type A hemophilia with coagulation factor VIII inhibitors or type B hemophilia with coagulation factor IX inhibitors and adults weighing at least 35 kg to prevent bleeding or reduce the frequency of bleeding episodes.